We are always evolving in an ever-changing industry.

Keep up-to-date with PrECOG by visiting our news page regularly.

Nature Medicine publishes phase 2 trial data showing durvalumab immunotherapy with standard chemotherapy improved survival in malignant pleural mesothelioma

In-depth molecular analyses of responding tumors provide insights into patient selection methods for this novel chemo-immunotherapy regimen, which is currently being evaluated in the DREAM3R phase 3 trial, open to patients in the US, Australia, and New Zealand Philadelphia, November 8, 2021—The PrE0505 phase 2 clinical trial results are published in the November 8 issue […]

Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma

After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial For Immediate Release March 17, 2021 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia—The DREAM3R phase three clinical trial is […]

Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib

Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence                 For Immediate Release May 29, 2020 Vienna, Brussels, Chicago, Philadelphia, Neu-Isenburg/Frankfurt, Pittsburgh—The Austrian Breast & Colorectal Cancer Study Group (ABCSG), Alliance Foundation Trials (AFT), […]

Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination should advance to a randomized phase 3 study For Immediate Release May 20, 2020 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia, PA—PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two […]

Oncolytics Biotech® and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer SAN DIEGO, CA, CALGARY, AB, and PHILADELPHIA, PA, October 22, 2019 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, […]